Search

Prostate Cancer Issue I

The ‘Prostate Cancer Focus 2021’ supplement from Urology News collates a range of articles covering the latest in the management of prostate cancer. The last year has seen plenty of innovation in the management of the condition, while the all-consuming...

RSM Paediatric Urology Meeting and Presidential Address 2023

The academic year of the Urological Section of the Royal Society of Medicine (RSM) started with a bang in October last year with the Paediatric Urology meeting, co-organised by Shabnam Undre (Paediatric Representative for BAUS and Consultant Paediatric Urologist East...

Sexual dysfunction following prostate cancer treatment

Prostate cancer is common with over 52,300 new cases diagnosed annually in the UK; this is expected to rise by 15% between 2023-2025 and 2038-2040 [1]. Radical prostatectomy continues to be the most common form of radical treatment for men...

Redundant! Do urological surgeons have a future in treating urological cancers? RSM Urology Section Meeting

December 2023 marked the latest RSM Urology Section event. Alongside the Winter Short Papers Prize presentations, the theme of the day was major urological cancers and the role of the urologist in patient management within the multidisciplinary team (MDT). We...

Thomas Molyneux and the lost bodkin

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In an earlier article we looked at one of the medals in the...

The running gleet: why venereal disease is so important to the history of urology

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). You might say that genitourinary infectious disease is a part of urology, but...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Dr Glaucomflecken: Stayin’ Alive

Peter Cackett spoke to ophthalmologist and social media sensation Dr Glaucomflecken about his early days in comedy, the role satire can play in impacting medical governance, and where he might take his brand of medical comedy next. It was towards...

Botulinum toxin – from the sausage poison to urology

Botulinum toxin is the first biological toxin to be licensed for use in treating human disease and since its first therapeutic use in the early 1980s for strabismus has become widely used in the fields of ophthalmology, cosmetic surgery, migraine...

Complications of CISC

Introduction Clean intermittent self catheterisation (CISC) was first introduced and popularised by Lapides in 1972. Since then its utilisation has become widespread and it is now commonly used throughout the world as the preferred means of facilitating complete and effective...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...